Anti-HMGB1 monoclonal antibodies have shown efficacy in preclinical models of inflammatory diseases, such as sepsis and acute liver injury, by neutralizing HMGB1 and reducing the inflammatory response. This evidence concerns the gene HMGB1 and Sepsis.